Lithium in Pregnancy: The Second-Trimester Nadir Most Clinicians Miss
Lithium in Pregnancy: The Second-Trimester Nadir Most Clinicians Miss
If you wait until the third trimester to increase the lithium dose, you've already missed the window. The largest drop in serum lithium occurs in the second trimester — and that's when most relapses begin.
Most clinicians remember two things about lithium in pregnancy: Ebstein anomaly and levels drop in the third trimester.
Both are partially true. Both are also actively misleading.
The Ebstein risk is dose-dependent and far lower than the 1970s registries suggested. And the largest reduction in serum lithium levels doesn't happen at the end of pregnancy — it happens in the middle.
This single pharmacokinetic fact changes how lithium should be monitored, when it should be adjusted, and why patients who appear "stable" at routine OB visits in the second trimester are often heading toward relapse no one sees coming.
The greatest drop in lithium levels — averaging 36% below preconception baseline — occurs in the second trimester, not the third.
Clinicians who wait for "late pregnancy" to act will leave patients subtherapeutic during a critical window. Adjust proactively based on levels — not symptoms alone.
What the Pharmacokinetic Data Actually Show
Wesseloo et al. (2017) remains the definitive dataset on perinatal lithium kinetics — 113 pregnancies, 1,101 serum levels. The trimester-by-trimester picture is more dramatic than most prescribers realize:
| Period | Mean Level Change | Clinical Action |
|---|---|---|
| First Trimester | ↓ 24% | Begin monthly monitoring; anticipate dose increase |
| Second Trimester | ↓ 36% (nadir) | Highest risk of subtherapeutic levels — act proactively |
| Third Trimester | ↓ 21% | Weekly monitoring from 34 weeks |
| Postpartum | ↑ 9% above baseline | Reduce to preconception dose immediately |
Clark et al. (2022) confirmed this in a separate cohort: lithium clearance increased by an average of 63.5% by the third trimester, and mood symptoms tracked closely with declining levels. Clearance returned to non-pregnant baseline only at 4–9 weeks postpartum.
The Lithium chapter is currently available for free preview. See how we approach perinatal medication decisions using a structured, step-by-step clinical framework.
Why the Second-Trimester Nadir Matters Clinically
1. The "Looks Stable" Trap
Mood symptoms lag pharmacokinetic changes. A patient whose lithium level has dropped 30% in week 18 may still appear stable at her week 20 OB visit — only to present with mixed features or hypomania at week 26.
By the time symptoms emerge, the patient has typically been subtherapeutic for weeks. Monthly serum levels are the only reliable early warning system.
2. The "Half-Treatment" Risk
Snellen and Malhi describe what they call the worst possible scenario in perinatal psychiatry: half-treatment. A subtherapeutic dose exposes the fetus to medication risk and the maternal risk of untreated bipolar disorder simultaneously.
The second trimester is precisely when patients drift into half-treatment silently. Proactive dose escalation isn't aggressive prescribing — it's risk minimization on both sides.
3. The Postpartum Mirror Image
Levels rebound to ~9% above preconception baseline almost immediately after delivery. A patient titrated up to maintain therapeutic levels during pregnancy who isn't promptly brought back down to her preconception dose is at high risk for postpartum lithium toxicity — the exact moment when she also faces a 25–50% risk of postpartum psychosis.
Standard post-cesarean ibuprofen 600 mg q6h can raise lithium levels 25–40% within days. Combined with the postpartum clearance rebound, this is the most predictable iatrogenic lithium toxicity scenario in obstetrics.
Flag the chart: "No NSAIDs — Lithium Patient." Acetaminophen is first-line.
In Practice — What You Should Actually Do
- Establish the preconception therapeutic level in a stabilized patient — this is the target throughout pregnancy
- Convert to BID dosing before conception — same total daily dose, lower peak concentrations
- Trimesters 1 & 2: Monthly serum lithium + creatinine. Anticipate dose increases — don't wait for symptoms
- Trimester 3 (from 34 weeks): Weekly levels until delivery
- Delivery: Hold lithium 24–48 hours before scheduled delivery or at onset of labor; aggressive IV/oral hydration
- Postpartum (Weeks 1–2): Restart at preconception dose within 6–12 hours of medical stabilization; twice-weekly levels; no NSAIDs
- Postpartum (Weeks 3–8): Weekly → biweekly monitoring as clearance normalizes
The goal during pregnancy is the minimum effective dose — emphasis on effective, not minimum.
Half-treatment is the worst of both worlds. If you're using lithium in pregnancy, use enough of it.
Want the Full Clinical Framework?
This post gives you the overview.
But real clinical decision-making requires more than that.
Inside our Perinatal Psychopharmacology: Rapid Decision Guide, each Mood Stabilizer Pregnancy Chapter is structured for rapid clinical decision-making:
Each Mood Stabilizer Pregnancy Chapter Is Structured for Rapid Clinical Decision-Making
- Executive Summary – rapid, high-yield clinical takeaways
- Teratogenicity & Fetal Risk – dose-stratified malformation data and absolute risk framing
- Pharmacokinetics in Pregnancy – trimester-specific clearance changes and dose-adjustment timing
- Monitoring & Fetal Surveillance – serum level frequency, fetal echo timing, anatomy ultrasound
- Peripartum & Delivery Management – labor-hold protocols, intrapartum hydration, cord blood workup
- Postpartum Stabilization & Relapse Prevention – restart timing, target levels, sleep protection
- Comparative Pregnancy Table – key data across agents with clear clinical interpretation
- Treatment Positioning – first-line vs. second-line vs. avoid during pregnancy
- Clinic-Ready Tools – patient counseling scripts, EMR documentation templates, decision flowcharts
- Clinical Pearls – high-yield insights for real-world decision-making
Standardized, clinic-focused chapters for every major mood stabilizer. Designed for real-world perinatal decision-making.
Explore the Full Series
This is part of the Pregnancy & Breastfeeding Psychopharmacology series.
View all upcoming chapters and the complete lecture schedule.
We continue to review and summarize clinically relevant research to support your daily practice.
Interested in Access to This & Other Clinically Relevant Lecture Series?
Join Psychiatry Education Forum
Academy Membership
- Best Value
- Maximum Saving
- Committed Learners
- Most Popular
Responses